INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

13th International Conference on Malignant Lymphoma

 

17-20 June 2015 Lugano
Close
N. Poster
Poster title
Applicant name
Status
  7-OT CHRONOS-1: Phase II trial of intravenous PI3K-&945;/-&946; inhibitor copanlisib in patients with relapsed/refractory indolent non-Hodgkins lymphoma Martin Dreyling Received Received
  8-OT Design of a Phase 1/2, open-label, dose-escalation trial of the Toll-like receptor antagonist IMO-8400 in patients with MYD88 L265P-positive diffuse large B-cell lymphoma James Baker Received Received
  9-OT Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update from a Phase II Clinical Trial Michael Wang Received Received
  10-OT Efficacy and Safety of Lenalidomide and Rituximab vs Placebo and Rituximab in a Phase 3 Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Rachel Sopko Received Received
  11-OT FIL-VERAL12: phase II randomized study with Rituximab-DHAP /- Bortezomib as induction in young relapsed/refractory Diffuse Large B-cell Lymphoma eligible to transplant. ANNALISA CHIAPPELLA Received Received
  13-OT The Elderly Project by the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Eldelry Patients with Diffuse Large B-Cell Lymphoma. Francesco Merli Received Received
  14-OT CLLR3 A randomized Phase II trial evaluating the chemotherapies FC/ B combined with GA101 followed by GA101 maintenance in relapsed/ refractory CLL Nadine Kutsch Received Received
  151-P T-cell subpopulations quantified by flow cytometry in lymph node cell suspensions identify a group of patients with follicular lymphoma with favorable outcome Laura Magnano Mayer Received Received
  154-P NR4A3 suppresses lymphomagenesis by induction of apoptosis and serves as a drug target for lymphoma therapy Alexander Deutsch Received Received
  157-P Prognostic impact of cell of origin profile in young patients with high risk diffuse large B cell lymphoma: results of the BIO-DLCL04 trial of Fondazione Italiana Linfomi ANNALISA CHIAPPELLA Received Received
  158-P Cell of origin is not associated with survival after DLBCL relapse Umar Farooq Received Received
  159-P Impact on survival of MYC genetic alterations but not MYD88L265P mutation in primary testicular DLBCL Alexandra Valera Received Received
  160-P MYD88 L265P mutations, but not other variants, identify a subgroup of patients with ABC diffuse large B-cell lymphoma, extranodal involvement and poor outcome JORDINA ROVIRA Received Received
  161-P MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma Ting-Xun Lu Received Received
  162-P Analysis of double-hit lymphoma cases by genetic subtype Daniel Landsburg Received Received
  163-P Molecular characterization of diffuse large B-cell lymphoma recurrences: clonal relationship and different modes of tumor evolution Darius Juskevicius Received Received
  164-P Relapsed DLBCLs present frequent copy number variations of genes involved in lymphomagenesis with different pattern between early- and late-relapsed DLBCLs BROSÉUS Julien Received Received
  166-P Prognostic Significance of Genomic Alterations in Mantle Cell Lymphoma Kurt Bantilan Received Received
  168-P PRIMA-1Met induces myeloma and mantle cell lymphoma cell death, by impairing ROS/GSH balance. Benoit Tessoulin Received Received
  169-P Chronic Lymphocytic Leukemia B-cells are rescued from apoptosis by extracellular vesicles from bone marrow mesenchymal stromal cells Emerence Crompot Received Received
  170-P Prognostic significance of TET and IDH mRNA expression in chronic lymphocytic leukemia Michal Van Damme Received Received
  171-P Optimal Treatment Strategies for Early-Stage Hodgkins Lymphoma with B Symptoms and Bulky Disease at Presentation Jay Reddy Received Received
  172-P Infradiaphragmatic Hodgkin Lymphoma: long term outcome improved by chemotherapy-radiotherapy VS chemotherapy alone. cédric rossi Received Received
  173-P Consolidation radiation after ABVD is effective treatment for ed patients with Hodgkins lymphoma (HL) with interim PET positive scans. Noelle ORourke Received Received
  174-P Pencil Beam Scanning Proton Therapy for Lymphoma Patients with Mediastinal Involvement: A Dosimetric Study and Preliminary Clinical Data Katerina Dedeckova Received Received
  175-P Cardiac Radiation Dose and Predicted Cardiac Mortality in the UK RAPID Trial in Early Stage Hodgkin Lymphoma David Cutter Received Received
  176-P Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free time points and survival comparison to the general population in British Columbia. Greg Hapgood Received Received
  177-P Healthcare utilization in the AETHERA trial: phase 3 study of brentuximab vedotin in patients at increased risk of residual Hodgkin lymphoma post ASCT vijayveer bonthapally Received Received
  179-P Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder (HL-PTLD): A Comparative Analysis of Prognosis and Survival Andrew Evens Received Received
  181-P First in-patient proof of safety and efficacy of a 4th generation chimeric antigen receptor-modified T cells for the treatment of R/R CD30-positive lymphoma Zhitao Ying Received Received
  182-P Chronic lymphocytic leukaemia treatment and outcome in the UKs population-based Haematological Malignancy Research Network Russell Patmore Received Received
  183-P Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B-CLL cells and FCGR3A polymorphism. A study of FCGCLL/MW and GOELAMS groups. Anne-laure Gagez Received Received
  184-P Results of a Phase II randomizing intensified rituximab pre-phase followed by standard FCR vs standard FCR in previously untreated patients with Active B-CLL. Stephane Lepretre Received Received
  185-P A Randomised Study of F(C)R in Fit, Elderly Patients with Chronic Lymphocytic Leukaemia (CLL) shows high response rates and a dose intensity effect Stephen Mulligan Received Received
  186-P Targeting Mutated BRAF with Vemurafenib is Safe and Highly Active in Relapsed/Refractory Hairy Cell Leukemia: a Phase-2 Italian Clinical Trial (HCL-PG01) Enrico Tiacci Received Received
  187-P The clinical course of patients with follicular lymphoma in the rituximab era inas el-najjar Received Received
  188-P Event-free Survival at 12 Months and Subsequent Overall Survival in Patients with Follicular Lymphoma Managed in the Rituximab Era Emmanuel Bachy Received Received
  189-P Follicular lymphoma and clinical characteristics of histologic transformation Miriam Mendez Received Received
  190-P RISK INCIDENCE OF FOLLICULAR LYMPHOMA TRANSFORMATION: MULTICENTRE RETROSPECTIVE ANALYSIS OF THE SPANISH GELTAMO GROUP Sara Alonso-Alvarez Received Received
  191-P Comparison of lenalidomide and rituximab with chemoimmunotherapy in patients with untreated grade 1-2 follicular lymphoma treated at the MD Anderson Cancer Center Chan Yoon Cheah Received Received
  192-P Extended Dosing Lenalidomide with Intensified Rituximab in Untreated Indolent NHL Nathan Fowler Received Received
  196-P Rituximab Maintenance (MR) improves PFS and OS in all Patients (pts) with Follicular Lymphoma (FL) - Individual Patient Data (IPD) meta-analysis Liat Vidal-Fisher Received Received
  199-P Higher risk of rituximab intolerance in patients with Waldenstrm Macroglobulinemia Jorge Castillo Received Received
  201-P Outcomes in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease patients treated with rituximab and liposomal doxorubicin (R-Dox) Thomas Uldrick Received Received
  202-P Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP vs R-CHOP in the phase 3 LYM-3002 study Gregor Verhoef Received Received
  204-P Clinical, metabolic and molecular responses with sequential R-CHOP, high-dose cytarabine, and iodine-131 tositumomab-based transplant in Mantle Cell Lymphoma Kurt Bantilan Received Received
  205-P Multi-center phase II study with lenalidomide plus rituximab as initial treatment for mantle cell lymphoma: survival update and health-related quality-of-life analysis Jia Ruan Received Received
  207-P Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma Peter Martin Received Received
  209-P High Dose Sequential Chemotherapy with Rituximab and ASCT as First Line Therapy in Adult MCL Patients: Clinical and Molecular Response of the MCL0208 Trial, a FIL Study. Sergio Cortelazzo Received Received
  210-P The standard, revised and a simplified International Prognostic Index reliably predict outcome in patients with PET/CT-staged DLBCL treated with R-CHOP Diego Villa Received Received
  211-P Female patients with DLBCL and involvement of the reproductive organs have poor outcomes and markedly increased risk of CNS relapse with R-CHOP(-like) therapy Tarec Christoffer El-Galaly Received Received
  212-P Evaluation of the site of central nervous system (CNS) relapse in patients with Diffuse Large B-cell lymphoma (DLBCL) by the CNS risk model Roopesh Kansara Received Received
  213-P Clinical and Treatment-Related Features Determining the Risk of Late Relapse in Patients with Diffuse Large B-cell Lymphoma Lena Modvig Received Received
  215-P Spleen involvement identified on baseline PET imaging influences outcome of young patients with high risk diffuse large B cell lymphoma treated with R-CHOP14 but not R-ACVBP Olivier Casasnovas Received Received
  217-P Vincristine omission, but not dose reduction, is associated with decreased survival in elderly DLBCL patients Salma Afifi Received Received
  218-P Outcome analysis of diffuse large B cell lymphoma (DLBCL) in HIV-infected and immunocompetent (IC) patients: The Swiss HIV Cohort study (SHCS) Annarita Conconi Received Received
  219-P Secondary CNS lymphoma in the rituximab-era: Data on the first 100 patients from a prospective registry Stephan Kreher Received Received
  220-P Dose-Dense Chemoimmunotherapy and Early CNS Prophylaxis for High-Risk DLBCL Interim Results from a Nordic Phase II Study Sirpa Lepp Received Received
  221-P Systemic high-dose methotrexate (HD-MTX) consolidation in poor-risk diffuse large B-cell lymphoma is associated with improved survival in Germinal Centre B-cell phenotype Michael Gilbertson Received Received
  222-P The addition of Rituximab to CODOX-M & IVAC in first Line therapy of poor risk Burkitt Lymphoma (IPI 3-5) yields an excellent outcome: a Phase 2 UK NCRI/LLR Trial (LLR 04058) andrew mcmillan Received Received
  225-P Prognostic impact of immunohistological profiling in primary CNS lymphoma Stephan Kreher Received Received
  226-P Addition of Rituximab to the Treatment of Newly Diagnosed Primary CNS Lymphoma is Associated with Improved Outcome: A French LOC Network study Emmanuel GYAN Received Received
  227-P BAM induction followed by autologous stem cell transplantation for patients with primary central nervous system lymphoma: a multicenter study from the Spanish group GEL-TAMO MIRIAM LÓPEZ-PARRA Received Received
  228-P High efficiency and tolerance of Temozolomide in relapse/refractory primary vitreo-retineal lymphoma: a multicentric study from the LOC network Sylvain Choquet Received Received
  229-P Temsirolimus for primary CNS lymphoma Stephan Kreher Received Received
  230-P Long-Term Outcome of 490 Patients with Early-Stage Extra-nodal Marginal Zone Lymphoma Sewit Teckie Received Received
  231-P Clinical Characteristics and Patterns of Care of Patients (pts) with Peripheral T-cell Lymphoma (PTCLs) according to age at time of diagnosis: A T-Cell Project snapshot. Monica Bellei Received Received
  232-P Characteristics and Patterns of Care of Patients (pts) =70 years with T-cell non-Hodgkin Lymphoma (TCL) in the United States (US) Chadi Nabhan Received Received
  233-P A large prospective multicenter study of peripheral T-cell lymphoma in Thailand: clinical, histopathology, treatment outcomes, and survival Jakrawadee Julamanee Received Received
  234-P A proposal of a new staging systemfor extranodal natural killer T-cell lymphoma, nasal-type: a multicenter study from Chinese Southwest Oncology Group (CSWOG) and Asia Lymphoma Study Group (ALSG) Tongyu Lin Received Received
  235-P A clinicopathological study of Lennert lymphoma and possible prognostic factors Daisuke Kurita Received Received
  236-P SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA IN THAILAND: CLINICAL OUTCOMES, TREATMENTS, AND PROGNOSTIC FACTORS Udomsak Bunworasate Received Received
  237-P Immunophenotypic heterogeneity of T-LGLL: clinical and biological implications Renato Zambello Received Received
  238-P Breast Implant Associated Anaplastic Large cell Lymphoma: a new distinct clinicopathologic entity. Camille Laurent Received Received
  239-P Molecular Heterogeneity of ALK-negative Anaplastic Large Cell Lymphoma Andrew Feldman Received Received
  243-P Polyethylene glycol conjugated asparaginase-CHOP in adult newly diagnosed extranodal NK/T-cell lymphoma: a multi-center prospective phase II study Wen Zheng Received Received
  244-P Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population Shunan Qi Received Received
  245-P Clinical Outcome of P-Gemox for Newly Diagnosed Stage III/IV or Relapsed/Refractory ENKTL HuiQiang Huang Received Received
  247-P The role of transplant in the treatment of Peripheral T-cell Lymphomas (PTCLs): an analysis from the T-Cell project database. Monica Bellei Received Received
  248-P Phase II study of SMILE chemotherapy for relapsed/refractory peripheral T-cell lymphoma Ritsuro Suzuki Received Received
  249-P Bendamustine treatment in refractory/relapsed T cell lymphomas: a retrospective multicenter study Emilie Reboursiere Received Received
  250-P The mTORC1 Inhibitor Everolimus Produces Tumor Responses in Patients with Relapsed T-cell Non-Hodgkin Lymphoma Thomas Witzig Received Received
  252-P Baseline metabolic tumor burden in DLBCL affects response to immuno-chemotherapy and patients outcome through influence of rituximab pharmacokinetics. A LYSA group study. Olivier Casasnovas Received Received
  254-P Role of bone marrow biopsy (BMB) in classic Hodgkin Lymphoma (cHL) staging in FDG-PET/CT era. benedetta puccini Received Received
  255-P Hodgkin Lymphoma: PET-CT or bone marrow biopsy? Zeinab Abou Yehia Received Received
  257-P PROGNOSTIC VALUE OF INTERIM FDG-PET/CT IN 100 DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP ACCORDING TO INTERPRETATION CRITERIA AND PRETHERAPEUTIC PROGNOSTIC FACTORS Caroline Faes Received Received
  258-P Blinded evaluation of the prognostic value of FDG-PET/CT after 2 cycles of RCHOP in DLBCL UK-NCRI study Mikhaeel George Received Received
  259-P No survival benefit associated with routine imaging for classical Hodgkin lymphoma in complete remission: A Danish-Swedish population-based study Tarec Christoffer El-Galaly Received Received
  261-P Biological Rational for Sequential Targeting of Bruton Tyrosine Kinase and Bcl2 to Overcome Cd40-induced BH3-mimetics Resistance in Mantle Cell Lymphoma David Chiron Received Received
  264-P Preclinical evaluation of the novel pleiotropic BCR kinase inhibitor IQS019 in in vitro and in vivo models of B lymphoid neoplasms Gael Roue Received Received
  266-P Transcriptomic profiling of response to PI3K inhibition by BKM120 in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) Micheal Coyle Received Received
  267-P Differential expression of PI3K isoforms/PTEN in follicular lymphoma and diffuse large B-cell lymphoma - therapeutic implications Lim Soon Thye Received Received
  268-P Inhibition of both PI3Ka and PI3Kd by Copanlisib is essential to attenuate both BCR-dependent and BCR-independent activation of NF&954;B and proliferation in DLBCL cells Juliane Paul Received Received
  269-P Pre-clinical lymphoma models show high sensitivity to the small molecule YK-4-279 Elaine Chung Received Received
  271-P The BET bromodomain inhibitor OTX015 (MK-8628) affects the expression of microRNAs involved in the pathogenesis of lymphoma: in vitro and in vivo evidence Afua Adjeiwaa Mensah Received Received
  272-P OTX015 (MK-8628) targets genes with high levels of promoter H3K4me3 involved in key signalling pathways in splenic marginal zone lymphoma and mantle cell lymphoma Chiara Tarantelli Received Received
  273-P Pixantrone has pre-clinical synergistic activity when combined with targeted agents in diffuse large B-cell lymphoma. Chiara Tarantelli Received Received
  274-P Novel CD37-Targeting Antibody-Drug Conjugate (ADC), IMGN529, Has Synergistic Activity in Combination with Rituximab in Non-Hodgkin Lymphoma (NHL) Models Angela Romanelli Received Received
  275-P A variant of obinutuzumab with abolished ADCC, ADCP and CDC is as efficient as rituximab in B cell depletion and antitumor activity Christian Klein Received Received
  277-P Targeting the MUC1-C oncoprotein is associated with downregulation of TIGAR and ROS-mediated cutaneous T-cell lymphoma cell death Salvia Jain Received Received
  278-P MYC and CHK1 Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models With Anti-Proteasomal Therapy Andrew Evens Received Received
  279-P Alisertib Exhibits Broad Activity And Selectively Synergizes With Romidepsin In Preclinical Models Of T-Cell Lymphoma Kelly Zullo Received Received
  280-P Interim Analysis of a Phase 1b Study Evaluating the Safety of GS-9820, a Second-Generation PI3Kd-Inhibitor, in Relapsed/Refractory Lymphoid Malignancies Arnon Kater Received Received
  282-P Everolimus plus R-CHOP as initial therapy for DLBCL: a phase I/feasibility study (NCCTG N1085 Alliance) Patrick Johnston Received Received
  283-P Safety and clinical activity of Temsirolimus in combination with Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma Mathias Witzens-Harig Received Received
  286-P Phase I dose-escalation study of BI 836826 in patients (pts) with relapsed or refractory non-Hodgkin lymphoma (NHL) of B cell origin Janet Lightwood Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
22:06
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

13th International Conference on Malignant Lymphoma

 

17-20 June 2015 Lugano
FAQs

You can now view the posters online!

Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 16/06/2015 TO 17/06/2017
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.13icml.2015 




PosterSessionOnline
Logo Draft
 
Logo Cert